A Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety and Efficacy of 28 Day Oral Administration of BAY 85-8501 in Patients with non-Cystic Fibrosis Bronchiectasis

Trial Profile

A Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety and Efficacy of 28 Day Oral Administration of BAY 85-8501 in Patients with non-Cystic Fibrosis Bronchiectasis

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2016

At a glance

  • Drugs BAY 85 8501 (Primary)
  • Indications Bronchiectasis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 10 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 13 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 21 Oct 2013 Planned end date changed from 1 Mar 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top